De novo somatic mutations in focal areas are well documented in diseases such as neoplasia but are rarely reported in malformation of the developing brain. Hemimegalencephaly (HME) is characterized by overgrowth of either one of the two cerebral hemispheres. The molecular etiology of HME remains a mystery. The intractable epilepsy that is associated with HME can be relieved by the surgical treatment hemispherectomy, allowing sampling of diseased tissue. Exome sequencing and mass spectrometry analysis in paired brain-blood samples from individuals with HME (n = 20 cases) identified de novo somatic mutations in 30% of affected individuals in the PIK3CA, AKT3 and MTOR genes. A recurrent PIK3CA c.1633G>A mutation was found in four separate cases. Identified mutations were present in 8-40% of sequenced alleles in various brain regions and were associated with increased neuronal S6 protein phosphorylation in the brains of affected individuals, indicating aberrant activation of mammalian target of rapamycin (mTOR) signaling. Thus HME is probably a genetically mosaic disease caused by gain of function in phosphatidylinositol 3-kinase (PI3K)-AKT3-mTOR signaling.
Malformations of cortical development (MCD) are increasingly recognized as an important cause of epilepsy and developmental delay. Disruption at various critical stages of cortical development-neuronal proliferation, migration and organization-leads to characteristic MCD 1, 2 . HME is a clinically devastating pediatric MCD characterized by enlargement of one cerebral hemisphere. Individuals with HME typically present with epilepsy, psychomotor disability, contralateral hemiparesis and hemianopsia 3 . Although most affected individuals have isolated forms of the disease, HME is occasionally associated with neurocutaneous syndromes, including tuberous sclerosis, hypomelanosis of Ito (HI) and Proteus syndrome (PS) 4 . Most affected individuals display progressive and catastrophic epilepsy, which is medically intractable and inevitably requires radical hemispherectomy (removal of the affected cerebral hemisphere) as a surgical treatment to relieve epilepsy and psychomotor disability 4 . HME occurs sporadically with no association with a specific ancestry group or gender. In addition, focal involvement of one affected hemisphere and discordance in monozygotic twins imply that somatic mutations occurring in cells within the affected area may contribute to HME during early cerebral development 3, 5 . However, the genetic etiology and pathogenesis of HME remain poorly understood.
The histopathological abnormalities in HME brain are described as cortical dyslamination, dysmorphic immature neurons and neuronal heterotopia, indicating primary defects in neuroglial differentiation, migration and cellular growth 6 . These pathological features are often shared with tuberous sclerosis complex (TSC), which is caused by mutations in TSC1 and TSC2 (ref. 7) . In fact, the link between TSC and mTOR signaling suggests the hyperactivation of mTOR signaling in HME 8 , but the wide range of altered genes in expression profiles 9 and the phenotypic variability and heterogeneity of diseased brain have hampered the identification of genetic causes.
Hemispheric surgical resection samples were available for 20 cases that met clinical and pathological criteria for HME 3 , and pre-surgical magnetic resonance imaging (MRI) scans were available for a subset of these ( Supplementary Fig. 1 and Supplementary Table 1) . Peripheral blood or saliva was obtained for probands and their parents and siblings in accordance with ethical approval. Due to the association of HME with Proteus syndrome 10 and the recent discovery in Proteus syndrome of a recurrent AKT1 c.49G>A (p.Glu17Lys) activating mosaic mutation 11 , we first assessed each available brain sample for the AKT1 c.49G>A mutation. No mosaicism was detected in AKT1 ( Supplementary Fig. 2) , suggesting that the connection between HME and Proteus syndrome may have other genetic origins.
De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly l e t t e r s
We next considered the possibility of a common, large de novo copynumber variation (CNV) such as those that have been reported in various neurodevelopmental disorders, including in epilepsy 12 . Using SNPGenotyping arrays 13 , we analyzed five pairs of HME brain-blood genomic DNA samples. In four of the five cases, we detected identical common CNVs in both brain and blood. In one case, HME-1573, we detected a de novo CNV on chromosome 1, but this CNV has been reported previously to be a normal variant 14 , suggesting that de novo CNVs are unlikely to be a major cause of HME (Supplementary Fig. 2) . We additionally considered the possibility of germline mutation, with silencing of the mutation occurring in healthy tissue due to mitotic recombination, akin to the mutation patterns observed for other recently reported mosaic phenotypes [15] [16] [17] . However, neither brain nor blood samples showed evidence of loss of heterozygosity (LOH), which is consistent with a previous finding of a lack of LOH in PTEN hamartoma tumor syndrome associated with an HME-like condition 18 (data not shown).
These results are consistent with the idea that HME is caused by de novo point mutations in critical regulatory gene(s). To test this model, we performed whole-exome sequencing on brain and peripheral blood DNA from five HME cases, with 93% exonic recovery at >30-fold coverage. To maximize the possibility of detecting somatic mutations at low copy in cellular heterogeneous brain tissues from HME cases, we used the recently developed JointSNVMix computational algorithm for the detection of somatic mutations in nextgeneration sequencing to simultaneously analyze sequencing data from blood-brain pairs and generate probabilities for de novo mutations at all detected alleles 19 . Using stringent criteria ( Supplementary  Fig. 3 ), we identified 26 candidate somatic mutations specific to HME brain. We then prioritized variants for those likely to substantially alter function by considering the biological importance of evolutionarily conserved sequences (Online Methods). With this prioritization, the top three missense mutations were found in PIK3CA (c.1633G>A; p.Glu545Lys) in HME-1573, AKT3 (c.49C>T; p.Glu17Lys) in HME-1565 and MTOR (c.4448C>T; p.Cys1483Tyr) in HME-1563 ( Fig. 1) , suggesting these as candidate genes involved in HME. None of these mutations were found in any blood sample (with a range of 49-298 reads per allele) but were identified in 9-17 reads from the affected hemisphere compared with 23-159 reference reads (9.7-28% of reference reads). Visualization of the reads in the Integrative Genomics Viewer suggested that the base quality of the mutant alleles was similar to that of the reference alleles, and there was no evidence that the variant calls were due to misalignment of the reads (Supplementary Fig. 3 ). In the remaining two cases, the evidence for somatic variants was less compelling, and none of the possible variants were confirmed using complementary methods. The data suggest that a fraction of the cells in the three samples contain de novo somatic mutations encoding altered amino acids.
As capillary (Sanger) sequencing cannot reliably detect somatic mutations in heterogeneous cell mixtures 20 , we instead used a modified single base-extension protocol followed by mass spectrometry analysis, which is able to detect somatic mutations at a frequency of as low as 3% in genetically heterogeneous samples 21 ( Supplementary  Fig. 3) . Reanalysis of the same DNA samples used for whole-exome sequencing again showed the absence of the mutant allele in blood but its presence in the brain, with similar mutation burden as that detected with Illumina sequencing (Fig. 1) . These somatic mutations were detected at a frequency of 36.6%, 40.4% and 8.1% in each brain sample (Fig. 1) . Using this technology, we further screened these mutations in the remaining 15 HME cases and identified 3 additional cases (HME-1855, HME-1916 and HME-1564) carrying the PIK3CA c.1633G>A (p.Glu545Lys) variant, each with a mutation burden of ~30% ( Table 1 and Supplementary Fig. 3 ). Therefore, we identified de novo somatic mutations in the PIK3CA, AKT3 and MTOR genes in 6 out of our total cohort of 20 HME cases (30%), with the PIK3CA c.1633G>A (p.Glu545Lys) variant being recurrent.
The differences in mutation burden between HME cases prompted us to examine this burden in anatomically defined brain regions in HME-1916 Right Left HME-1564 HME-1573 HME-1855 HME-1565 HME-1563 l e t t e r s available samples from the cases. In HME-1573 with the PIK3CA mutation, we found a mutation burden of 21-40% in orbital, frontal, central operculum and occipital regions (Fig. 2) . In HME-1565 with the AKT3 mutation, we found a mutation burden of ~16-30% in parietal, central operculum and temporal regions. Notably, in HME-1563, where tissue was available only from multiple distinct regions of the central operculum, we found the MTOR mutation burden to be quite variable, ranging from 8-36%, even within this one region. These data indicate that HME harbors admixtures of mutant alleles that make up between 8-40% of the alleles within affected brain regions. As the human genome is diploid and because we expect these mutations to be present in only one of the two alleles, we infer that a substantially higher percentage of cells carry the HME-associated mutations in these various brain regions than in other tissues, although the exact percentages remain to be determined. The PIK3CA, AKT3 and MTOR genes encode well-known regulators of the mTOR signaling pathway (Fig. 3) , which is involved in cell growth and metabolism. Whereas PIK3CA and MTOR have widespread expression, AKT3 is most strongly expressed in the nervous system. Akt3-null mice have smaller brains than wild-type mice, as a result of reduced cell number and size 22, 23 , and an activating point mutation in Akt3 results in seizure susceptibility 24 . The PIK3CA gene encodes the catalytic domain of the PI3K protein known as p110α, which uses ATP to phosphorylate phosphatidylinositol (PtdIns), PtdIns 4-phosphate (PtdIns(4)P) and PtdIns 4,5-bisphosphate (PtdIns(4,5)P 2 ). Upon stimulation with extracellular signals, such as insulin and platelet-derived growth factor, the resultant production of PtdIns 3,4,5-trisphosphate (PtdIns(3,4,5)P 3 ), one of the most potent bioactive lipids, functions to activate proteins in the AKT family by binding to the pleckstrin homology (PH) domain. AKT family proteins can directly phosphorylate the mTOR protein, which is the product of the MTOR gene. The identification of de novo mutations in these three genes, which are central to the mTOR pathway, is evidence that disrupted signaling underlies HME. (c) HME-1563 was sampled multiple independent times in the central operculum region (yellow circles), but samples could not be precisely aligned anatomically. Left, MRI scans; circles indicate brain areas examined by mass spectrometry analysis. Right, each sample aliquot was analyzed by mass spectrometry for mutation burden, describing variation in mutation burden across anatomical locations.
npg l e t t e r s A large body of work has implicated somatic mutations in these genes in the pathogenesis of solid malignancies, and two of the three mutant alleles that we identified were previously reported in cancers. The PIK3CA p.Glu545Lys variation within the helical domain of the p110α protein was identified in tumors of the colon and brain 25, 26 and constitutively activates the mTOR pathway 27 . The AKT3 p.Glu17Lys variation within the PH domain was identified in melanomas and results in increased AKT3 phosphorylation in transfected cells 28 . Although the transversion we identified in MTOR has not been encountered previously in human disease, other activating point mutations in this gene have been found in cancer 29, 30 . Nevertheless, it remains to be determined whether the mTOR p.Cys1483Tyr variation in HME leads to increased signaling.
To determine whether the affected individuals in our study had aberrant mTOR signaling, we immunostained brain sections of HME cases (HME-1573, HME-1565 and HME-1563) with an antibody specific to the phosphorylated epitope of the S6 protein in a standard assay for the activation of mTOR signaling. Cells with the morphology of cytomegalic neurons were strongly labeled for phosphorylated S6 in the 3′-diaminobenzidine (DAB) staining of HME brains (Fig. 3) . In addition, we co-immunostained for the neuronal marker MAP2, comparing samples with age-matched, similarly processed non-HME cortical hemisphere, and we found a marked increase in the number of cells that were positive for phosphorylated S6 and greater intensity of staining for phosphorylated S6 in cytomegalic neurons of HME cases (Fig. 3) . We conclude that the mutations identified here are associated with increased mTOR signaling in affected brain regions.
On the basis of these data and those previously published, we propose a model of HME involving somatic de novo gain of function in the mTOR pathway. Mutations were identified in 6 of the 20 samples using exome data from the first 5 cases, so it is possible that there are other mutations in these genes or in completely different genes in the remaining cases. No clear genotype-phenotype correlation was observed in the affected individuals identified to date (Supplementary Table 1) , which is not unexpected, given the potential for heterogeneity in the genetic cause and mosaicism rates and the potential for allelic heterogeneity, any of which might influence phenotype. In addition, the connection to TSC suggests the possibility of using mTOR inhibitors to treat individuals with HME who have aberrant mTOR signaling because the TSC-encoded proteins Hamartin and Tuberin function as negative regulators of the mTOR pathway [31] [32] [33] [34] . Brain pathology from TSC tubers shows hyperactivation of downstream mTOR signaling, and inhibition of mTOR with rapamycin (also known as sirolimus) is of proven benefit in the treatment of TSC-related brain lesions 35 .
We note that subject HME-1563 with the MTOR mutation also carries a diagnosis of hypomelanosis of Ito, a dermatological condition caused by segmental depletion of melanocytes. The co-occurrence of HME and hypomelanosis of Ito has been observed repeatedly [36] [37] [38] , suggesting a common genetic origin, but the basis of hypomelanosis of Ito remains unknown. We speculate that activating mutations in the mTOR pathway may account for at least some cases and suggest that these somatic mutations may extend to other areas of the body and result in loss of mutation-carrying melanocytes in the affected areas. Similarly, the PIK3CA mutation in HME-1855 may extend to hypertrophic regions (the right hand and foot), thereby causing the overgrowth of affected tissues. In both cases, it might be possible to test this model by assessing mutation burden in affected regions.
Our results are consistent with at least three potential explanations for the strict unilateral hemisphere affectation in HME. The first model involves a substantial somatic mutation burden in a subset of progenitors contributing to one hemisphere, without such burden in progenitors in the contralateral hemisphere. The second model involves approximately equal mutation burden in the two hemispheres, which is exacerbated by an unidentified spatially restricted change to signaling, such as epileptic seizures. The third model involves a combination of these two models, with uneven mutation burden in the two hemispheres that is exacerbated by unilateral signaling. Although access to tissue from the uninvolved hemisphere in HME is lacking, it should be possible to test these models using animal models of HME. Accessing brain tissue from humans with neurological disease will be increasingly important for future research.
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Growth factor receptors Figure 3 The de novo mutations identified in HME correlate with hyperactive mTOR signaling. (a) Schematic of the PI3K-AKT3-mTOR pathway and downstream phosphorylated ribosomal protein S6 kinase (P-S6K) and phosphorylated ribosomal protein S6 (P-S6). (b) HME pathological samples show an increased percentage of cells with positive staining for P-S6 and MAP2. Left P-S6, biotin-streptavidin DAB staining; right, P-S6, fluorescence-conjugated staining. MAP2 was used to identify neurons. Scale bars, 100 µm. (c) Quantification of P-S6-positive cells from 5-7 representative cortical areas per case. **P < 0.01 (relative to non-HME samples, one-way ANOVA with Bonferroni posttest, n > 50 cells per region). Error bars, s.e.m.
npg l e t t e r s and Phenotypes (dbGAP). Reference sequences for the affected genes include NM_006218 (PIK3CA), NM_181690 (AKT3) and NM_004958 (MTOR).
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